East Tamaki-based Fisher & Paykel Healthcare Corporation [FPH] has reported total operating revenue for the full year ended March 31, 2023 of $1.58 billion, down 6 per cent [or 9 per cent in constant currency] from the 2022 financial year.
Net profit after tax [NPAT] was $250.3 million, a 34 per cent decline from the 2022 financial year, or a 39 per cent decline in constant currency.
For the second half, operating revenue grew 14 per cent to $890.5 million, or 12 per cent growth in constant currency from the second half of 2022, driven by strong growth in hospital new applications consumables and OSA masks revenue.
Managing director and CEO Lewis Gradon said, “We are coming out of three financial years that were impacted by the Covid-19 pandemic and our people, suppliers and customers have worked tirelessly to meet global demand surges.
“The second half result was encouraging as market conditions progressed towards more of a normal state and both our Hospital and Homecare product groups delivered good growth.”
At current exchange rates, guidance assumptions for the 2024 financial year include no significant respiratory disease events, and result in full year operating revenue of about $1.70b, with similar revenue growth rates for both hospital and homecare product groups.
